Cook MyoSite

Cook MyoSite Incorporated is developing and commercializing technology related to the collection, selection and expansion of human skeletal muscle cells. Separate research and clinical programs have been established to assist the research community in performing muscle-related research and to develop cellular products for the treatment of a variety of muscle-related disorders.

Cook MyoSite is part of Cook Medical, the first company to introduce minimally invasive interventional devices in the United States. Today, Cook Medical participates in all global markets, integrating device design, biopharma, gene and cell therapy and biotech to enhance patient safety and improve clinical outcomes. In 2002, Cook Medical formed Cook MyoSite to guide the company into the expanding world of cellular technologies.

Research Products

Changing the way skeletal muscle research is performed.

Previous research utilizing cells isolated from animal muscles has provided a glimpse of the diverse array of regenerative capacity and healing responses elicited by resident progenitor cells. To assist research in this field and facilitate the discovery process, Cook MyoSite is now offering primary human skeletal muscle derived cells (SkMDC) and other complementary products to the research community.
Learn more about our research products.

Clinical Products

Technology and clinical products.

The clinical need for more effective and durable therapies is the impetus behind the advancement of biologics for the treatment of many diseases. Cook MyoSite’s initial therapeutic focus is stress urinary incontinence (SUI), a clinical condition that is underserved and lacking effective options. Cook MyoSite is developing a novel autologous cell therapy for treating SUI from concept to clinical investigations.
Learn more about our clinical products.